2023-03-31-accounts

Report and Accounts 31 March 2023

Research That Saves Lives

leukaemiamyelomaresearchuk.org

Registered charity number 1161622 (England & Wales), SC046106 (Scotland), Leukaemia and Myeloma Research UK Ltd

Company Limited by guarantee Registered number 09481278

Research That Saves Lives

Leukaemia and Myeloma Research UK Ltd Unit 127, North Mersey Business Centre, Woodward Rd, Knowsley Industrial Park, Liverpool, Merseyside, L33 7UY

Tel: [phone]

Web: www.leukaemiamyelomaresearchuk.org

Email: [e-mail]

Charity Number 1161622 Company Number 09481278

Follow us on Twitter: https://twitter.com/lmruk_org

Facebook: https://www.facebook.com/leukaemiamyelomaresearchuk.org

MODEL CELL BIOBANK [ele￿ih thdi live Together we can beat cancer Annual Report 2023

Table of contents

About Us ..........................................................................................................	3
Stem Cells .......................................................................................................	4
Charitable Activities........................................................................................	5
Chairman’s Report ..........................................................................................	6
Operation Director’s Report ...........................................................................	7
MCB Service..................................................................................................	9
Overview ......................................................................................	9
Case Study....................................................................................................	11
Research Priorities.......................................................................................	12
Fundraising and Volunteers.........................................................................	13
Thanks...........................................................................................................	14
Trustees and Staff ........................................................................................	14
Accounts .......................................................................................................	15

https://leukaemiamyelomaresearchuk.org 2

About Us

Leukaemia & Myeloma Research UK Ltd wants to prevent people dying from blood cancer through more effective treatment in the future. We are willing to fight blood cancer regardless of how long it might take.

Founded in 2015, our mission is to prevent people dying from blood cancer through prevention, research and more effective treatment.

Unfortunately, blood cancer affects a large number of people. Every 13 minutes, someone in the UK is told they have a blood cancer. That’s around 110 people per day, 40,000 people per year. There are an estimated 4,700 leukaemia deaths every year, that’s 13 every day!

We are aiming to become the UK’s leading charity in supporting efforts to combat the three major types of blood cancer. The work we do helps fund vital stem cell research, raises awareness of stem cell therapies and helps families protect their children’s future health by storing their cord blood stem cells at the time of birth.

There are 3 main types of cancers of the blood; they are lymphoma, leukaemia and myeloma.

treat patients with blood cancer, particularly through stem cell transplants. We do this by:

The blood is made up of three different types of cells:

• Red blood cells which carry the oxygen around the body • White blood cells which fight and stop infections

• Actively supporting stem cell research into blood cancers • Raising awareness of stem cell therapies

• Platelets which help the blood to clot

• Provide information about blood cancers and treatment options

The course of treatment given will depend on the type of cancer. The most common treatments are chemotherapy, radiotherapy and in some instances, a stem cell transplant.

• Protecting the vulnerable by offering qualifying expectant mothers, with a family history of cancer, the opportunity to store their baby’s umbilical cord blood stem cells at the time of birth, in case they are needed in the future to treat that child or another member of the family if they’re a suitable match.

In essence, the Charity wants to eradicate blood cancer once and for all. One of the ways we are aiming to achieve that is through advancing our understanding of stem cells and how we can use them to

This service is called Model Cell Biobank (MCB).

3 Tel: [phone]

Stem Cells

In humans, there are two types of stem cells: embryonic stem cells and adult stem cells, which are found in various tissues.

Adult stem cells are the primary focus of the research that the Charity supports. They typically generate the cell types of the tissue in which they reside.

For example, a blood-forming adult stem cell in the bone marrow normally gives rise to the many types of blood cells. It is generally accepted that a blood-forming cell in the bone marrow—which is called a hematopoietic stem cell— cannot give rise to the cells of a very different tissue, such as nerve cells in the brain.

Where are stem cells found?

There are four known accessible sources of autologous adult stem cells in humans:

• Bone marrow which requires harvesting by drilling into bone (typically the femur or iliac crest). This is done under a general anesthetic.

• Blood, which requires extraction through apheresis, wherein blood is drawn from the donor (similar to a blood donation), and passed through a machine that extracts the stem cells and then returns the blood to the donor.

• Adipose tissue (lipid cells), which requires extraction by liposuction

cancers, such as sickle cell anaemia and aplastic anaemia.

• Umbilical cord blood - these stem cells can be collected from the umbilical cord blood just after birth.

For most types of blood cancers, for example: leukaemia, lymphoma and various anaemia’s, the treatments use allogeneic stem cell transplants (someone else’s stem cells). The reason for this is that the person may have a genetic predisposition to the disease; their genes have a defect that predisposes them to that disease.

What can stem cells be used for today?

There are treatments where Hematopoietic Stem Cell Transplants (HSCT) - the transplantation of blood forming stem cells - is a standard treatment. For some diseases they are the only therapy, and in other diseases they are only employed when front-line therapies have failed or the disease is very aggressive.

However there are various types of cancers (some myelomas, plasma cell leukaemia, some anaemia’s and solid tumours) that are treated using autologous stem cells (using your own stem cells).

There are other blood disorders that can be treated with stem cells that aren’t

https://leukaemiamyelomaresearchuk.org 4

Charitable Activities

Providing Information Throughout the year we have shared facts about blood cancer, including the signs, symptoms and treatments. We have achieved this through our regular newsletter, social media channels, website, and our blood cancer booklet. This provides patients with clear and informative advice that would answer their questions, explain terminology, discuss treatments so they are better prepared and able to make informed choices.

We produce a quarterly newsletter that shines a spotlight on our inspirational fundraisers and their stories; highlights our exciting plans for the future and provides information relating to blood cancer. It is available from our website free of charge.

Medical Research

Leukaemia & Myeloma Research UK Ltd allocate research grants to those who uphold our primary objectives. These are to benefit the public, in particular by research into the nature, causes, diagnosis, prevention, treatment and cure of leukaemia and myeloma.

Our current funding priorities are to advance understanding of stem cells and how they can

be used to treat blood cancer patients. All grant applications are reviewed by the Charity’s Research and Review Committee, an independent panel of experts. The Charity is a member of the Association of Medical Research Charities, the AMRC.

Fundraising Activities

Over the last year, the Charity expanded its textile recycling project so it now includes local schools to the Merseyside and Greater Manchester areas. This is with the aim of raising awareness of both blood cancer and of the environmental benefits of recycling. It also continues to raise valuable funds for the charities work.

In conjunction with this, our fundraisers have been busy running events from cake sales to sky dives. This has secured £127,500 of funding to support our services and help in the fight against cancer.

Model Cell Biobank Service This service was established to support families who are on low income, have a history of cancer in the family, to store their babies cord blood stem cells at the time of birth. These cells are stored for 25 years in case that child, or another member of the family, needs them in the future to treat a disease.

The cord blood stem cells can be used today instead of bone marrow stem cells to treat blood cancer and genetic disorders. In fact, recent studies show that over 80 diseases could be treated using cord blood stem cells.

5 Tel: [phone]

Chairman’s Report

It remains one of our key focuses, to widen awareness of blood cancer. We have achieved this in a number of ways.

In May, the Charity engaged in World Blood Cancer Day, sharing informative posts on social media and producing an article for Charity Today. Following this, in June we marked National Myeloma Awareness week, where we shared our informative blog ‘What is Myeloma?’ to help raise awareness of the signs and symptoms.

A poll carried out by leading charities found that out of 2,000 participants only 1% were able to name the 4 main symptoms of leukaemia. This highlighted the urgent need to raise public awareness of the symptoms of this type of blood cancer. In response, during Blood Cancer Awareness Month in September we helped

people identify common symptoms and also raised awareness of the different treatment options available, particularly cord blood banking and its many benefits.

In November, we celebrated World Cord Blood Day, sharing information and networking with like minded bodies.

In January, we launched the School Textile Recycling Scheme in the Liverpool and Greater Manchester areas. The team have been working hard to engage with schools and spread the message.

In March we celebrated Myeloma Awareness Month by educating people about this form of blood cancer and the common symptoms to look out for. We teamed up with former NHS worker and myeloma survivor, Jan Cashen (pictured above) and the West Lancs & Merseyside Myeloma

Support Group, to promote the importance of funding blood cancer research and the value of support groups to those being treated or recovering from the disease.

I would like to take this opportunity to thank all our volunteers and fundraisers without their support we wouldn’t be able to continue to offer the services that we do.

Sergejs Vinogradovs Chair, Leukaemia and Myeloma Research UK Ltd

https://leukaemiamyelomaresearchuk.org 6

Operation Director’s Report

I would like to start by celebrating our inaugural winners of the charities Fundraiser of the Year award, Elaine and Peter Kinsella. They raised an incredible £8,000 for three charities.

We have had some fantastic fundraising efforts this year from walking and cycling to skydives! To give a few examples, 21-year-old Ben Saunders (pictured below) took part in an epic skydiving challenge to raise money for Leukaemia & Myeloma Research UK Ltd in memory of childhood friend, William Pearce.

For the first time ever we secured places in the London to Brighton Charity Bike Ride in September 2022. We were incredulous at the response - with 74 riders taking part, including 50 employees from professional machinery and service provider Lister Wilder. The Lister Wilder Team

raised £22,250 which LMRUK are honoured to have allocated to a grant named the Lister Wilder Research Grant (pictured right). Someone who knows the importance of our research work is Research Review Committee member, Dr Rhys Morgan. Dr Morgan raised more than £1,400 in the ride, which he completed in memory of his younger brother David.

Further support came from members of the congregation at a church in Coventry have helped to raise over £5,000 for blood cancer research in memory of a much-loved member of their congregation who passed away from the disease.

We were fortunate to be awarded some corporate support including becoming Charity of the Year for Bognor Regis Golf Club. Ladies

Captain, Heather Tidy, kindly secured £2,767 over the year.

A Scottish recruitment company celebrated its 35th birthday in business with a £3,000 donation.

We were fortunate to be one of the 20 good causes the Orion Group, headquartered in Inverness, who donated a total of £35,000 to, as a way of marking its anniversary.

Our cord blood banking service continues to grow from strength to strength. At the turn of the year we began a partnership with Smart Cells

----- Start of picture text -----
Tel: [phone]
----- End of picture text -----

7

International to procure, process and store cord blood stem cells through LMRUK’s cord blood banking service, which we call MCB.

We are extremely grateful to the generous funding received from Fundraising Support Ltd who have helped this service support even more families.

Much Loved is a special memorial website in tribute to loved ones, where people can share thoughts and stories with family and friends. Through this scheme, donations can be made to charity. We are incredibly grateful to all the donations we have received this year in memory of loved ones.

I would like to say a huge ‘thank you’ to all our fundraisers for their hard work and to our dedicated staff team and partners who have pulled together to make 202223 such a huge success. All of our fundraisers are important - we simply would not be able to run these services without their help.

Dr Joanna Tilley Operations Director, Leukaemia and Myeloma Research UK Ltd

https://leukaemiamyelomaresearchuk.org 8

MCB Service

Overview

The Model Cell Biobank (MCB) service allows the storage of a child’s umbilical cord blood stem cells at the time of birth, in case they or another member of the family needs them in the future to help in the treatment of a disease. It may be possible to use the stem cells to treat blood cancers or in emerging therapies to treat diseases such as diabetes, cerebral palsy and Parkinson’s disease. Clinical trials are being performed all over the world looking at the potential use of stem cells to treat new diseases and hopefully further breakthroughs.

When a baby is born and the umbilical cord is cut, the placenta and umbilical cord are normally thrown away. The blood that remains in the cord and the placenta contains stem cells. The Charity offers a service to collect these stem cells without any risk to the mother and baby, and to store them in case that child or another member of the family needs them in the future.

the age of majority, at which point, ownership transfers to the child. After 25 years, the cells can be privately stored, donated for research, offered to a public bank, or destroyed. Consent from the child will be sought at this point and we would strongly encourage the donation of any remaining cells to public banks.

The cord blood banking service is available to qualifying expectant mothers who live in the UK. They must be in receipt of Housing Benefit, Council tax or Universal Credit (at least one of these) and must meet the following criteria:

• The stem cells will be used to treat the child, or another member of the family, for a medically attested treatment; • There is a history of cancer in the immediate family.

We recently extended the project to support low-income families by implementing a part funded service for those who have medical history, but are not on benefits.

Smart Cells Technical is our chosen partner to procure; process and store cord stem cells under its Human Tissue Authority licence.

Smart Cells has a strong reputation for standards it applies to the storage and processing of stem cells derived from umbilical cord and peripheral blood, bone marrow, now extending to many types of tissues for human application or transplant.

Smart Cells not only works to the highest standards, it also has an ethical approach, which aligns with our charity, something we are proud of.

The cord blood stem cells are stored on behalf of the child for 25 years. The mother is the legal guardian of the cells until the child reaches

Tel: [phone]

9

Advantages of Cord Blood Stem Cells

Today, cord blood banking is changing lives and there have already been more than one million stem cell transplants around the world since the 1980s.

The stem cells in your baby’s cord blood are fully developed adult stem cells, which are the building blocks of the blood immune system. These stem cells can be used instead of bone marrow stem cells to treat blood cancers and genetic disorders. Cord blood stem cells have many advantages including: • They are easily available, having already been harvested and stored;

Future Plans

• Cord blood stem cells can be stored for many years - the longevity of these cells has proved they are as good 30 years later as on as the day they were first extracted and stored.

• A new born baby has been exposed to fewer viruses and infections and so the stem cells are less likely to transmit infection and react with the patient;

• Cord blood stem cells offer the life-saving option of a transplant and avoids the invasive, painful and expensive procedures of other stemcell collection, such as bone marrow;

There are now a number of stem cells banks in the UK and interest in private storage has grown considerably over the last few years.

However, this is hugely expensive and means many people cannot take advantage of this service as the cost is too prohibitive.

There is also a huge shortage of stem cells being collected from BME communities - leaving them vulnerable and without a choice of treatment should they fall ill with blood cancer or another disease. Those from a minority ethnic background have only a 37% chance of finding a bone marrow match from an unrelated donor, whereas

someone from a white Caucasian background has a 72% chance.

For this reason, over the next financial year we are promoting our funded stem cell collection and storage service to BME communities to increase awareness of stem cell treatments and encourage donations from this sector.

https://leukaemiamyelomaresearchuk.org 10

Case Stud – Natalia’s Stor y y

The Cord Blood Stem Cell Pilot project was launched in 2017 and since this time we have received nearly 300 enquiries – which far exceeded our expectations. To date, this has resulted in 36 successful cord blood stem cell extractions.

Our very first client was Natalia and this is her story: I am 24 years old and have 3 children aged six, three, and six months old. Whilst pregnant with my third child, I was diagnosed with lymphoma cancer in my neck. When I found out that I had cancer I was filled with guilt for my children – I was so worried that this could be hereditary and passed onto them. After doing some research into my family, I found out that my auntie had been diagnosed with cancer and that my grandfather had died from it. I had to do something to protect my children.

Cord blood stem cell storage and transplants are very costly so many cannot afford to use this potentially lifesaving service. This would certainly have been the case for us, however Leukaemia & Myeloma Research UK Ltd’s Model Cell Biobank offers a fully-funded service to qualifying families. If it wasn’t for this service we would never have been able to afford to store our baby’s cord

of whom should be a strong match should any of them ever need it.

blood stem cells.

The process was really straightforward, we were sent a kit which contained all the information that we needed for the cord blood storage and collection.

Ever since my diagnosis I have felt an enormous sense of guilt about the chance of any of my children getting cancer – it is a mother’s worst nightmare.

When I went into labour, a phlebotomist came to the hospital and waited until the baby was delivered. Then they took a sample of cord blood to collect the stem cells, which caused no harm or pain to our baby or myself, and packaged it safely and securely.

I am incredibly grateful to have found out about this potentially lifesaving service, and even if we don’t use the stored cord blood stem cells, it is reassuring to know that they will not go to waste.

My reason for storing my son’s cord blood stem cells is not for my use but for my children, all

11 Tel: [phone]

Research Priorities

team at the Department of Medicine at the University of Oxford £25,000 to engineer and screen different antibodies to find a way to stop mutations in the FLT3 protein from causing Acute Myeloid Leukaemia (AML) in patients.

Leukaemia & Myeloma Research UK Ltd offer research grants to those who uphold our primary objectives: to protect and promote the health of the public, in particular by research into the nature, causes, diagnosis, prevention, treatment and cure of leukaemia and myeloma.

“On average less than 15% of AML patients will survive longer than five years. FLT3 is a significant contributory factor, it’s really pushing this disease and we have to shut it down,” said Dr Fernandes.

The Trustees funding priorities are to advance understanding of stem cells and how they can be used to treat blood cancer patients, particularly through stem cell transplants. In July 2022 we awarded Dr Ricardo Fernandes and his

The grant money will help the team move the research forward more quickly and

allow them to focus all their attention over the next year on tackling the FLT3 receptor problem.

It will ultimately help in the development of a prototype for a drug that can be used as an effective treatment in the future. Dr Ricardo Fernandes hopes that moving forward, this type of research could be applicable to other types of cancer as well.

Dr Rhys Morgan

Dr Paul Spencer Hole

Lecturer in Biomedical Sciences in Department of Biochemistry and Biomedicine, at the University of Sussex.

Senior Research Scientist. Has been engaged in academic research at Cardiff University and extends his experience in a clinical-stage biopharmaceutical company.

Professor Joseph R. Slupsky

Reader in Department of Molecular and Clinical Cancer Medicine, University of Liverpool. He is Principal Investigator of the Liverpool Blood Disease Biobank and Academic Lead University of Liverpool Technology Directorate Cell Sorting and Flow/Mass Cytometry Facility.

Dr Claire Seedhouse

Associate Professor within Division of Cancer and Stem Cells, University of Nottingham. She is Principle Investigator and research group leader in Blood Cancer at the University of Nottingham.

Dr Ceri Bygrave

A Consultant Haematologist and Myeloma Lead at the University Hospital of Wales and a member of the UK Myeloma Forum Executive Committee and the UK Myeloma Research Alliance.

Dr John Jones

Senior Clinical Lecturer – Brighton and Sussex Medical School, Honorary Consultant Haematologist – Kings Dr Salvatore Papa College Hospital NHS Trust, London and An Associate Professor at Leeds University whose Eastbourne District General Hospital. research speciality is in lymphoma and myeloma.

https://leukaemiamyelomaresearchuk.org 12

Fundraisin and Volunteers g

Churchgoers fundraising campaign in memory of a much-loved friend and wife.

Members of the congregation at a church in Coventry have helped to raise over £5,000 for blood cancer research charity, Leukaemia & Myeloma Research UK Ltd (LMRUK) in memory of a much-loved member of their congregation who passed away from the disease.

Pat Elliman from Coventry was about to begin a round of stronger chemotherapy treatment for Acute Myeloid Leukaemia (AML) in hospital in December 2020 when she passed away in the arms of her devoted husband Malcolm.

Well known for her generous and kind nature, as well as a talent for baking, Pat was an active member of Holyhead Road United Reformed Church in the city for many years. Since her death, other members of the church have been holding a range of fundraising events after selecting LMRUK as its chosen charity for 2022.

The fundraising effort has been coordinated by Karen Adams, supported by her mum, Sue Adams and Malcolm. It was

August 2020 and Pat had just given her 97th donation of blood when she arrived back home feeling very tired. Within a few days, blood tests and a bone marrow analysis revealed she had incurable AML FLT3 WILD.

emergency admissions for infections. It was only two days before her death that she was told her condition was worsening and she chose to undertake the stronger chemotherapy treatment. Malcom says “I could write a book about Pat’s trials and bravery during those five months but also understand that many people have the same experience. The haematology staff were incredibly kind and caring throughout and I can’t thank them enough. “I am grateful that the church Pat loved so much is raising money for LMRUK in memory of her, but also to help other sufferers. I will do everything I can to support this fundraising,”

Malcom has already been part of the fundraising effort by doing a sponsored walk from Coventry to Kenilworth, a walk he and Pat would often do. Other fundraising events have included quiz and bingo evenings, a sponsored spell event by members of the 7th Coventry Girls’ Brigade Company, a secondhand book sale at a local shopping centre, craft and cake sales.

Karen and fellow family members completed a sponsored step challenge while on holiday in Devon. They set themselves a target of 600,000 in eight days and managed over 900,000.

During the Covid-19 pandemic she endured three courses of chemotherapy over several months, much of which had to take place at her home because of lockdown restrictions. But she also had to endure many visits to hospital for treatment, including two

“We were originally aiming to raise £4,000, but our current total is over £5,000 – the highest amount we have raised for a chosen project”, said Karen. The cheque was presented to LMRUK in January 2023.

13 Tel: [phone]

Thanks to Funders

• Chamifealion Charitable Trust

• Boden

• Albert Hunt Trust

• Tesco Groundworks

• Ambergate Charitable Trust

• Ladbrokes Coral

• May Hearnshaw Charitable Trust

• T K Maxx and Homesense

• Santa Barbara Heights Charitable Trust

• LPC Group

• Thomas Sivewright Catto Charitable Settlement

• Ian Askew Charitable Trust

• Grace Trust

• Henhurst Trust

• The Tony Bramall Charitable Trust

• Family Rich Charities Trust

• Gisela Graham Foundation

• Stella Symons

• Gledswood Charitable Trust

• Marsland Mcadoo

• Dorothy Holmes Charitable Trust

• Orion Group (see photo)

• Arnold Clark Community Fund

Staff and Committee Members

Trustees 2022-2023

• Sergejs Vinogradovs (Chair)

• Tatjana Vinogradova

• Victoria Kieran

• Julija Sidorika

Thanks to Individuals and supporters

• Best Freelance Design Ltd

• Smart Cells International

• Dr Hannah Hunter – Consultant Haematologist

• Fundraising Support Ltd

• KOR Communications Limited

Staff Team

• Dr Joanna Tilley - Interim Operations Director

• Lucy Heron - Office Manager / Senior MCB Call Centre Manager

• Phlebotomy UK Ltd

• Research Review Committee

• Richard Thompson - Call Centre

• Kate Williams - PT Fundraiser

https://leukaemiamyelomaresearchuk.org 14

Income and Expenditure Account for the year ended 31st March 20�3

Accounts

leukaemiamyelomaresearchuk.org Registered charity number 1161622 (England & Wales), SC046106 (Scotland), Company Limited by guarantee Registered number 09481278

Accounts 31 March 20�3

15

Leukaemia & Myeloma Research UK Ltd

Report and accounts for the year ended 31 March 2023

Contents

	Page
Charity information		1
Trustees' Annual Report		1
Statement of directors' responsibilities		5
Independent Examiner's Report		7
Funds Statements:-
Statement of Financial Activities		9
Statement of Financial Activities - Prior Year statement		10
Movements in funds		12
Income and Expenditure account		13
Balance sheet		14
Notes to the accounts		15

Leukaemia & Myeloma Research UK Ltd

Company Registration Number - 09481278

Trustees' Annual Report for the year ended 31 March 2023

The Trustees present their Report and Accounts for the year ended 31 March 2023, which also comprises the Directors' Report required by the Companies Act 2006.

Reference and administrative details

The charity name.

The legal name of the charity is:- Leukaemia & Myeloma Research UK Ltd.

The charity is also known by its operating name, LMR UK Ltd.

The charity's areas operation and UK charitable registration.

The charity is registered in England & Wales with the Charity Commission in England & Wales (CCEW) with charity number 1161622.

The charity is also registered in Scotland, with charity number SC046106 as it has operations in Scotland.

The charity does not operate in any overseas jurisdictions.

Legal structure of the charity

The charity is constituted as a company limited by guarantee, registered under the Companies Acts . The governing document of the charity is the Memorandum and Articles of Association establishing the company under company legislation.

The governing document is dated 10 March 2015

There are no restrictions in the governing documents on the operation of the Charity or on its investment powers other than those imposed by Charity Law.

By operation of law all, trustees are directors under the Companies Act 2006 and all directors are trustees under Charities legislation and have responsibilities, as such, under both company and charity legislation.

The trustees are all individuals.

1

Leukaemia & Myeloma Research UK Ltd

Company Registration Number - 09481278

Trustees' Annual Report for the year ended 31 March 2023

The principal operating address, telephone number, email and web addresses of the charity

Unit 127, North Mersey Business Centre Woodward Road, Liverpool Merseyside, L33 7UY Telephone [phone] Email Address [e-mail] Web address https://www.leukaemiamyelomaresearchuk.org/

The registered office of the charity for Companies Act purposes is the same as the operating address shown above.

The Trustees in office on the date the report was approved were:-

Sergejs Vinogradovs Tatjana Vinogradova Julija Sidorika Victoria Kieran

The following persons served as Trustees during the year ended 31 March 2023 :-

The trustees who served as a trustee in the reporting period were as shown above, and there were no changes during the year, or in the period between the year end and the approval of the accounts.

All the trustees are also members of the charity.

Objects and activities of the charity

The purposes of the charity as set out in its governing document.

The objectives of the charity are set out in the Memorandum of Association of 14 July 2015. They are:

1. to protect and promote the health of the public in particular by research into the nature, causes, diagnosis, prevention, treatment and cure of leukaemia and myeloma.

2. development of research into practical applications for the prevention. Treatment and cure leukaemia and myeloma and raise public understanding of such matters.

2

Leukaemia & Myeloma Research UK Ltd

Company Registration Number - 09481278

Trustees' Annual Report for the year ended 31 March 2023

Structure, governance and management of the charity

The methods used to recruit and appoint new charity trustees.

Proposals for new Trustees are made by the Chair after making appropriate enquiries. Appointments are then made by election by the existing board of Trustees.

Accountants

KBH Accountants Ltd - 255 Poulton Road, Wallasey, CH44 4BT

3

Leukaemia & Myeloma Research UK Ltd

Company Registration Number - 09481278

Trustees' Annual Report for the year ended 31 March 2023

Financial review

Restricted Revenue Funds Total Funds Unrestricted Revenue Funds available for the general purposes of the charity Net income	2023 £ 35,474 311,735 40,586 352,321	2022 £ 30,559
		285,330 31,517
		316,847

Financial review of the position at the reporting date, 31 March 2023 .

Overall surplus stands at £352,321 and will be distributed in following way: £150,000 for the Reserves; £65,000 for Research grants, and £137,321 for charity development, including MCB and the e-shop.

The trustees consider the financial performance by the charity during the year to have been satisfactory.

Policies on reserves.

The trustees collectively aim to maintain free reserves in unrestricted funds within a range equivalent to twelve months of unrestricted charitable expenditure. This targeted level is deemed essential by the trustees to ensure an adequate financial cushion for covering support and governance costs. The Reserves Policy will undergo an annual review, aligning with the scrutiny of the charity's annual accounts.

In light of the events of the past year, marked by a significant surge in inflation, escalating living costs, and an increased risk of economic downturn, the trustees have determined that a prudent Reserves amount must be set at £150,000. This decision is reflective of the charity's commitment to financial resilience and its responsiveness to the evolving economic landscape.

Availability and adequacy of assets of each of the funds

The board of trustees is satisfied that the charity's assets in each fund are available and adequate to fulfil its obligations in respect of each fund.

Details of The Independent Examiner

Olivia Higgins FCCA

Member of Chartered Certified Accountants 255 Poulton Road Wallasey Wirral

CH44 4BT

4

Leukaemia & Myeloma Research UK Ltd

Company Registration Number - 09481278

Trustees' Annual Report for the year ended 31 March 2023

Statement of the Directors Trustees' Responsibilities

The charity's trustees are responsible for the preparation of the accounts in accordance with the terms of the Companies Act 2006, the Charities Act 2011 and the Charities (Accounts and Reports) Regulations 2008. Notwithstanding the explicit requirement in the extant statutory regulations,the Charities (Accounts and Reports) Regulations 2008, to prepare the financial statements in accordance with the SORP 2005, in view of the fact that the SORP 2005 has been withdrawn, the Trustees determined to interpret this responsibility as requiring them to follow current best practice and prepare the accounts according to the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), .

In particular, the Companies Act 2006 and charity law require the Board of Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity as at the end of the financial year and of the surplus or deficit of the charity. In preparing those financial statements the Board is required to :-

• to prepare the accounts in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law).

• select suitable accounting policies and apply them consistently;

• make judgements and estimates that are reasonable and prudent;

• prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business;

• state whether applicable accounting standards and statements of

recommended practice have been followed, subject to any material

departures disclosed and explained in the financial statements;

The law requires that the trustees must not approve the accounts unless they are satisfied that they give a true and fair view of the state of affairs of the charity and of the surplus or deficit of the charity for the year.

The Trustees are also responsible for maintaining adequate accounting records which disclose with reasonable accuracy at any time the financial position of the charity and which are sufficient to show and explain the charity's transactions and enable them to ensure that the financial statements comply with the Companies Act 2006 and comply with regulations made under the Charities Act. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Trustees are also responsible for the contents of the Trustees' report, and the statutory responsibility of the Independent Examiner in relation to the Trustees' report is limited to examining the report and ensuring that , on the face of the report, there are no material inconsistencies with the figures disclosed in the financial statements.

5

Leukaemia & Myeloma Research UK Lld Coryany Redstralion N￿ber. 09481278 Trust88s' Annual Report tor the year 8nded 31 March 2023 mel￿d ot preparation of a¢counts- Small company provlsiong Thè flnanclal slalem&nts are sel out on pages 9 10 33. The linan¢ial statements have been prepar8d imKAemenllro Iho FRS 102 SORP IStal8m&nt of Recommend￿1 Practice for Accounllng and Rewrling by Charrflesl 2015. las amend￿1 by thg Bulletin iss{J￿1 in Oclobgr 2018 and applicab￿ lo a(tounting p9rths beginnlng on or aftor fjst January 20191, trho SORPI, ar¥J in atXorthr￿O wlh the Financkil Repor￿￿￿ Standard 102, 1gffe¢dv¢ 1st January 20181 Thgse flnancial slal8menls have been prepared in actordance lh8 provtsions in P8Jl 15 01 th ConN)anios Act 2006. applicablè to eornpanies sthject lo th8 small companies reglm&. Thls report was aFprov&l by th8 board of trusieos on l/IDIAm6u2023. TATJANA VINIXRADOVA Diiedor aJKI TriJst8e

Leukaemia & Myeloma Research UK Ltd

Report of the Independent Examiner to the Trustees of the charitable company on the accounts for the year ended 31 March 2023

I report to the Trustees on my examination of the financial statements of the charitable company on pages 9 to 33 for the year ended 31 March 2023 which have been prepared in accordance with the Charities Act 2011 (the Act) and with the Financial Reporting Standard 102, (effective 1st January 2016) as modified by FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), published by the Charity Commission in England & Wales (CCEW) , and under the historical cost convention and the accounting policies set out on page 15.

Respective responsibilities of the Trustees and the Independent Examiner and the basis of the report

As described on page 5, you, the charitable company's Trustees, who are also the Directors of the Company for the purposes of Company law, are responsible for the preparation of the financial statements in accordance with the Companies Act 2006, the Charities Act 2011 and all other applicable law and with United Kingdom Generally Accepted Accounting Practice, applicable to smaller entities, and for being satisfied that the financial statements give a true and fair view.

The Trustees consider that the audit requirement of Section 144(1) of the Charities Act 2011 (the Act) does not apply, and that there is no requirement in the memorandum and articles of the charity for the conducting of an audit, and that the accounts do not require an audit in accordance with Part 16 of the Companies Act 2006 and that no member or members have requested an audit pursuant to Section 476 of the Companies Act 2006. As a consequence, the Trustees have elected that the financial statements be subject to independent examination.

Having satisfied myself that the financial statements are not required to be audited under any legal provision, or otherwise, and are eligible for independent examination, it is my responsibility to:-

a) examine the financial statements of the charity under Section 145 of the Act;

b) follow the applicable procedures in the Directions given by the Charity Commission under section 145(5)(b) of the Act.

Basis of Independent Examiner's Statement and scope of work undertaken

Since the charitable company's gross income exceeded £250,000, the charitable company's examiner must be a member of a body listed in section 145 of the Act. I confirm that I am qualified to undertake the examination because I am an authorised member of Chartered Certified Accountants , which is one of the listed bodies.

I report in respect of my examination of the charity's financial statements carried out under s145 of the Act. In carrying out my examination, I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act setting out the duties of an independent examiner in relation to the conducting of an independent examination. An independent examination includes a review of the accounting records kept by the charitable company and of the accounting systems employed by the charitable company and a comparison of the financial statements presented with those records. It also includes consideration of any unusual items or disclosures in the financial statements, and seeking explanations from you, as Trustees, concerning such matters. The purpose of the examination is to establish as far as possible that there have been no breaches of charity legislation and that, on a test basis of evidence relevant to the amounts and disclosures made, the financial statements comply with the SORP.

The procedures undertaken do not provide all the evidence that would be required in an audit, and information supplied by the Trustees in the course of the examination is not subjected to audit tests or enquiries and does not cover all the matters that an auditor would consider in arriving at an opinion. The planning and conduct of an audit goes beyond the limited assurance that an independent examination can provide

Consequently, I do not express an audit opinion on the view given by the financial statements, and in particular, I express no opinion as to whether the financial statements give a true and fair view of the affairs of the charity, and my report is limited to the matters set out in the statement below.

I planned and performed my examination so as to satisfy myself that the objectives of the independent examination are achieved and before finalising the report I obtained written assurances from the Trustees of all material matters.

7

Leukaemla & Myeloma Research UK Ltd Ind8pendonl Exomlngrf8 Stalernent, Report aThl Oplnlon Subla(# to tha Ilmitaliors upon SLV¢ of my as detsilwl atrn, I have Lxyryleted nw 8xamlnalh)n'. arnl ¢an ¢onllrrn Ihat'.- The arts)uNs ol this rtharilJle cryany aro not I￿1￿c{l to aLxSted Part 16 of t1￿ Col￿anIeS Acl 2006. Thiq is a r￿rt In reSp￿t of an exanalbn ¢arried wi und8T 145 of the in a￿ordaI￿ w￿h DIrec￿on8 given by the Cl4rfty CoTrffji8gon uTrJer s8Cth)n 145(5llbl of may te applicat4e' and ttrAt no M￿arE￿ rnaitèri have cm to my attenlkn kn vilh exam1r￿On giving me cause to bolleve that In any rnaleriaj respecl-. )xunUng rettwds were not k￿1 in resFtt ol the tharity as raq￿r￿j by Sethon 3B6 of the Cor￿JanIeS Ad 21x6 aTrJ Seclkjn 130 01 Tha P<t &11., thè fina￿al staternents do not ac￿r￿ Mth ltrb)so rwds.. th8 finan(yal slatements do not compty wth retwirwrnts COr￿mIng Ihe lomi arvj ojntenl ol unt5 set out in secuon 396 01 the CoThpanbps AL 20¢￿ other than any requirernenl that the &counts a arnl fairf vivw, whth ￿ ncrt a nHtter ¢￿$￿J8red a8 partofan inderthjent eKamlnatknn.' hav¢ not been prepared In a¢xordarKe 1lh tho nwlhods aNI ￿n￿pIeS set out in the FRS 102 SORP Slaternènt of Rècomrnellded Practke lor Accounb"rJ and Repjrting by Charthesl 2015. las ary￿Thjed by tll Bulleyn Isswl in (ktcthr 2018 aTrJ ￿￿able to all ￿MInting Winnir¥J on or after1 st January 20191. The SORPI. I have no ￿ncernS arKI have cTh &ross ￿ olhw in C{m￿l0n vrith the examiialbn to attenknon shoukl be In this reFiNt in order to enabl• a sNoper ￿K￿r*[KI￿j of the finwKial slatements to be reach6d. (m￿18 HIG￿￿% FC leFeTrJent Examln KBH Accountantg Ud Chartered Certified Acc(Juntants 255 P(MJrton Road Walks8y WItTai CH44 48T Thls report was svJned on )zJ

Leukaemia & Myeloma Research UK Ltd - Statement of Financial Activities for the year ended 31 March 2023

Statement of Financial Activities (including the Income and Expenditure Account for the year ended 31 March 2023, as required by the Companies Act 2006)

Current year Unrestricted Funds 2023 £ Income & Endowments from: Donations & Legacies A1 138,590 Charitable activities A2 18,635 Investments A4 665 Other A5 50,063 Total income A 207,953 Expenditure on: Raising funds B1 19,100 Charitable activities B2 162,448 Total expenditure B 181,548 Net income for the year 26,405 Transfers between funds C - Net income after transfers A-B-C 26,405 26,405 Reconciliation of funds:- E Total funds brought forward 285,330 Total funds carried forward 311,735 SORP Ref Net movement in funds	Current year Restricted Funds 2023 £ 35,385 1,918 - - 37,303 - 28,234 28,234 9,069 - 9,069 9,069 31,517 40,586	Current year Total Funds 2023 £ 173,975 20,553 665 50,063 245,256 19,100 190,682 209,782 35,474 - 35,474 35,474 316,847 352,321	Prior Year Total Funds 2022 £ 138,627 17,846 27 50,109
			206,609
			9,095 166,955
			176,050
			30,559 -
			30,559
			30,559 286,288
			316,847

The 'SORP Ref' indicated above is the classification of income set out in the formal SORP documents. As required by paragraph 4.60 of the SORP, the brought forward and carried forward funds above have been agreed to the Balance Sheet.

A separate Statement of Total Recognised Gains and Losses is not required as this statement includes all recognised gains and losses.

All activities derive from continuing operations

The notes attached on pages 15 to 33 form an integral part of these accounts.

9

Leukaemia & Myeloma Research UK Ltd - Statement of Financial Activities for the year ended 31 March 2023

Leukaemia & Myeloma Research UK Ltd - Analysis of prior year total funds, as required by paragraph 4.2 of the SORP

Income & Endowments from: Donations & Legacies A1 Charitable activities A2 Investments A4 Other A5 Total income A Expenditure on: Raising funds B1 Charitable activities B2 Total expenditure B Net income for the year Net income after transfers Reconciliation of funds:- E Total funds brought forward Total funds carried forward Net movement in funds SORP Ref	Prior Year Unrestricted Funds 2022 £ 126,387 17,846 27 50,109 194,369 9,095 153,973 163,068 31,301 31,301 31,301 258,527 289,828	Prior Year Restricted Funds 2022 £ 12,240 - - - - 12,240 - 12,982 12,982 (742) (742) (742) 27,761 27,019	Prior Year Total Funds 2022 £ 138,627 17,846 27 50,109 206,609 9,095 166,955 176,050 30,559 30,559 30,559 286,288
			316,847

All activities derive from continuing operations

A separate Statement of Total Recognised Gains and Losses is not required as this statement includes all recognised gains and losses.'

The notes attached on pages 15 to 33 form an integral part of these accounts.

10

Leukaemia & Myeloma Research UK Ltd - Statement of Financial Activities for the year ended 31 March 2023

Leukaemia & Myeloma Research UK Ltd - Resources applied in the year ended 31 March 2023 towards fixed assets for Charity use:-

2023 towards fixed assets for Charity use:-
Funds generated in the year as detailed in the SOFA Resources applied on functional fixed assets Net resources available to fund charitable activities	2023 £ 35,474 (1,599) 33,875	2022 £ 30,559 -
		30,559

The resources applied on fixed assets for charity use represents the cost of additions less proceeds of any disposals.

The notes attached on pages 15 to 33 form an integral part of these accounts.

11

Leukaemia & Myeloma Research UK Ltd - Statement of Financial Activities for the year ended 31 March 2023

Movements in revenue and capital funds for the year ended 31 March 2023

Revenue accumulated funds

Unrestricted Funds 2023 £ Accumulated funds brought forward 285,330 26,405 311,735 (From)/To unrestricted revenue funds - Closing revenue funds 311,735 Summary of funds Unrestricted and Designated funds 2023 £ Revenue accumulated funds 311,735 Recognised gains and losses before transfers	Restricted Funds 2023 £ 31,517 9,069 40,586 - 40,586 Restricted Funds 2023 £ 40,586	Total Funds 2023 £ 316,847 35,474 352,321 - 352,321 Total Funds 2023 £ 352,321	Last year Total Funds 2022 £ 286,288 30,559
			316,847 -
			316,847
			Last Year Total Funds 2022 £ 316,847

The notes attached on pages 15 to 33 form an integral part of these accounts.

12

Leukaemia & Myeloma Research UK Ltd - Statement of Financial Activities for the year ended 31 March 2023

Leukaemia & Myeloma Research UK Ltd Income and Expenditure Account for the year ended 31 March 2023 as required by the Companies Act 2006

Income Income from operations Interest receivable Other operating income Gross income in the year before exceptional items Gross income in the year including exceptional items Expenditure Charitable expenditure, excluding depreciation and amortisation Depreciation and amortisation Fundraising costs Governance costs Total expenditure in the year Tax on surplus on ordinary activities Retained surplus for the financial year Net income after tax in the financial year Net income before tax in the financial year	2023 £ 194,528 665 50,063 245,256 245,256 189,657 1,025 19,100 - 209,782 35,474 - 35,474 35,474	2022 £ 156,405 27 50,109
		206,609
		206,609
		165,910 625 9,095 420
		176,050
		30,559 -
		30,559
		30,559

All activities derive from continuing operations

In accordance with the provisions of the Companies Act 2006, the headings and subheadings used in the Income and Expenditure account have been adapted to reflect the special nature of the charity's activities.

The notes attached on pages 15 to 33 form an integral part of these accounts.

13

Leukaomlo & Ilyetoma Research UK Ud. B919￿e Sheela5 at 31 PA&r¢h 21>23 2023 202 Flx¢d ass•19 Tangible &%sets Total flxed assets 1￿24 1m4 1,250 1,250 Curreni 88eeis B1 17MI 17,507 4,432 299,864 321.803 Ca¥h at and In hand Toial currnnt asso18 J,510 356.r Crethi¢XS.' amwrrt# th￿vIlh￿ ono 10 C1 15,S&31 I6.2￿ Nut currenta8&el• 35).497 315,597 Th8 tolal net a8$0ts of Ih•¢h4rMy 316,847 Tho lolal n•1 oflha ch8rltyer8 fwthl tythtrfuNl# ofthè clwlty. OB follws:. Re8trkt8d fvr RgstrIGf8d R8V8nuB Fun(k 13 31,517 31517 Unr•irlO￿ Fund8 Unr8Stricted Flevenw Fun(Is 13 03 311,T 285330 311.735 285,330 D881gMtBd Fund& Tol81 chartylurhlg 316,8 Thg ECA4P Ref above 18 ts da8sWIkn of Sh88t In tho fOrTh￿ SOFIP doLunen15. As requlr8d by paraoraph 4.60 01 the SORP. tr￿ht forward and (aFrled lorward fynd5 abov6 have b88n agréed SOFA.. The dir8ctcxs are salsfiad thai lh8 enbllBd to 8X8rnrknn framlhe rwBMrernBnt l) Lthln an undgr s¢ctlon 477 of the Companle5 Ac12006. The ￿ML￿$ r￿t requir8d th8 ottskn an authl in ac•JJrdancelth swlkjn 476ofthe Th8 dractors ackn￿￿edge their r6sponsiltle8 for the Iwurerv￿tS ol th8 20C6 wlth resp$¢t lo a(£¥Jundng records al￿ th8 [￿Spara￿on of aLfOUtts. T.w chartty IB $ublect to Inder￿TrI0￿t EKaft¥naiknn un¢Je¥ Larity Iwathn. aThJ the rep)rt of the 1Tr8nd8nt EKarnln8r18 on paa8 8. linandl Stalw￿n[S have bgen prq)ared in 8CWrda￿ with tr pr¢y¢tsbw In Part 1S of the Cwanl95 lt 2006. a￿kable lo c(¥TFanies subj.to the smal t￿mpan*S wim8. TATJANA VIIthX4RAfK)VA Trusteo Apwoved tylh8 trjard of Injstees rwJtssaUachBd on pap$ 15 to 33 loffli an ￿rt 0fth￿ ar￿￿ 14

Leukaemia & Myeloma Research UK Ltd

Notes to the Accounts for the year ended 31 March 2023

1 Accounting policies

Policies relating to the production of the accounts.

Basis of preparation and accounting convention

The accounts have been prepared on the accruals basis, under the historical cost convention, and in accordance with the Financial Reporting Standard 102, (effective 1st January 2016) and 'FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), published by the Charity Commission in England & Wales (CCEW) , effective January 2016, , and in accordance with all applicable law in the charity's jurisdiction of registration, except that the charity has prepared the financial statements in accordance with the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), in preference to the previous SORP, the SORP 2005, which has been withdrawn, notwithstanding the fact that the extant statutory regulations, the Charities (Accounts and Reports) Regulations 2008 refer explicitly to the SORP 2005. This has been done to accord with current best practice.

Risks and future assumptions

The charity is a public benefit entity.

This policy is a formal acknowledgement that LMRUK is committed to maintaining a strong risk management framework and making every effort to manage risk appropriately by maximising potential opportunities whilst minimising the adverse effects of risks. It should be used to support the internal control systems of the charity, enabling LMRUK to respond to operational, strategic and financial risks regardless of whether they are internally or externally driven.

Policies relating to categories of income and income recognition.

Nature of income

Gross income represents the value, net of value added tax and discounts, of goods provided to customers and work carried out in respect of services provided to customers.

Categories of Income

Income is categorised as income from exchange transactions (contract income) and income from non-exchange transactions (gifts), investment income and other income.

Income from exchange transactions is received by the charity for goods or services supplied under contract or where entitlement is subject to fulfilling performance related conditions. The income the charity receives is approximately equal in value to the goods or services supplied by the charity to the purchaser.

Income from a non-exchange transaction is where the charity receives value from the donor without providing equal value in exchange, and includes donations of money, goods and services freely given without giving equal value in exchange.

15

Leukaemia & Myeloma Research UK Ltd

Notes to the Accounts for the year ended 31 March 2023

Income recognition

Income, whether from exchange or non exchange transactions, is recognised in the statement of financial activities (SOFA) on a receivable basis, when a transaction or other event results in an increase in the charity’s assets or a reduction in its liabilities and only when the charity has legal entitlement, the income is probable and can be measured reliably.

Dividends are accrued when the shareholder’s right to receive payment is established.

Income subject to terms and conditions which must be met before the charity is entitled to the resources is not recognised until the conditions have been met.

All income is accounted for gross, before deducting any related fees or costs.

Income from legacies

Income from legacies is recognised when the charity has sufficient evidence that a gift has been left to them, that where required, probate has been granted, the executor is satisfied that the property in question will not be required to satisfy claims in the estate, that it is probable that the amount will be received by the charity, and the amount to be received can be estimated with sufficient accuracy, and that any conditions attached to the legacy are either within the control of the charity or have been met.

Where a payment is received from an estate or is notified as receivable by the executors after the reporting date and before the accounts are authorised for issue but it is clear that the payment had been agreed by the executors prior to the end of the reporting period, then the amount concerned is treated as an adjusting event and accrued as income in the accounting period if receipt is probable.

Where the charity has established entitlement to a legacy but there is uncertainty as to the amount of the payment, details of the legacy are disclosed as a contingent asset until the criteria for income recognition are met. Where a legacy is subject to the interest of a life tenant, the legacy is not recognised as income until the death of the life tenant.

If it is doubtful that full settlement of a legacy debtor will be received, then an adjustment is made to reduce the amount of the legacy debtor and legacy income rather than charging the adjustment as expenditure in the Statement of Financial Activities

16

Leukaemia & Myeloma Research UK Ltd

Notes to the Accounts for the year ended 31 March 2023

Donated goods, facilities and services

Donated fixed assets are recognised at the current fair value. All such donations are recognised as donation income, and debited to fixed assets.

Donated goods that are not fixed assets are accounted for at a fair value, unless it is impractical to reliably measure the value of the donated items.

In the absence of any direct evidence of fair value of donated goods, then a value is derived from the cost of the item to the donor or, in the case of goods that are expected to be sold, the estimated resale value after deducting any anticipated costs of sales.

If it is impracticable to measure the fair value of goods donated for resale, or the costs of valuation outweigh the benefits, the donated goods are recognised as income when sold, with an equivalent amount being recognised as an expense.

The costs of goods donated for distribution to beneficiaries is deemed to be the fair value of those goods upon receipt. When the goods are distributed freely or for a nominal consideration, then the carrying amount is adjusted at the time of sale, to the value at the point of distribution and the adjustment is shown as a cost of donations made.

The carrying amount of any stock held for distribution is assessed for impairment at the reporting date. All donated goods are recognised as donation income, and debited to trading stock.When trading stock is subsequently sold, or appropriated to meet an expense, then the carrying value of the stock is recognised as an expense. In accordance with the SORP, goods donated for distribution to beneficiaries, or for consumption by the charity are included in 'legacies and donations '. Goods donated for resale are included in 'Income from other trading activities'

The cost of any stock of goods donated for distribution to beneficiaries is deemed to be the fair value of those gifts at the time of their receipt. If the goods held are to be distributed freely or for a nominal consideration, then the carrying amount is subsequently adjusted to reflect the lower of deemed cost adjusted for any loss of service potential and replacement cost. Replacement cost is the economic cost incurred if the charity was to replace the service potential of the donated goods at its own expense in the most economic manner.

Donated services and facilities (including seconded staff and use of property) are included in the accounts on the basis of the value of the gift to the charity.

All donated services and facilities are recognised as donation income when received,(provided the value of the gift can be measured reliably) and recognised as an expense with an equivalent value.

Policies relating to expenditure on goods and services provided to the charity.

Allocating costs to activities

Direct costs that are specifically related to an activity are allocated to that activity. Shared direct costs and support costs are apportioned between activities.

The basis for apportionment, which is consistently applied, and proportionate to the circumstances, is :-

Staffing - on the basis of time spent in connection with any particular activity. Staffing - on a per capita basis, based on the number of of people employed within any partiular activity. Premises related costs - on the proportion of floor area occupied by a particular activity.

Non specific support costs - on the basis of the usage of resources, in terms of time taken, capacity used, request made or other measures

Estimation techniques used in apportioning costs - give details

17

Leukaemia & Myeloma Research UK Ltd

Notes to the Accounts for the year ended 31 March 2023

Policies relating to assets, liabilities and provisions and other matters.

Stocks and work in progress

Stock is valued at the lower of cost and net realisable value.

Debtors

Debtors are measured at their recoverable amounts at the balance sheet date.

Creditors and provisions

Liabilities are measured at their settlement amount. A liability is recognised for the amount the Charity anticpates it will pay to settle the deb t or the amount it has received as an advance payment for goods or services it must provide.

2 Liability to taxation

The Trustees consider that the charity satisfies the tests set out in Paragraph 1 Schedule 6 of the Finance Act 2010 for UK corporation tax purposes. Accordingly, the Charity is potentially exempt from taxation in respect of income or capital gains received within categories covered by chapter 3 part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied exclusively on the specific charitable objects of the charity and for no other purpose. Value Added Tax is not recoverable by the charity, and is therefore included in the relevant costs in the Statement of Financial Activities.

3 Winding up or dissolution of the charity

If upon winding up or dissolution of the charity there remain any assets, after the satisfaction of all debts and liabilities, the assets represented by the accumulated fund shall be transferred to some other charitable body or bodies having similar objects to the charity.

No employees received emoluments (excluding pension costs) in excess of £60,000 per annum.

4 Defined contribution pension schemes

Any liabilites and assets associated with the scheme are shown under debtors and creditors.

5 Remuneration and payments to Trustees and persons connected with them

The trustees received payments in the amount of £1,292 as travel expenses related to providing services for clothing collection.

No persons connected with the trustees received any remuneration from the charity, or any related entity.

6 Trustees' expenses

There were no Trustees' expenses in the year and in the prior year.

18

Leukaemia & Myeloma Research UK Ltd

Notes to the Accounts for the year ended 31 March 2023

7 Tangible fixed assets

Current Year Cost At 1 April 2022 Additions At 31 March 2023 Depreciation At 1 April 2022 Charge for the year At 31 March 2023 Net book value At 31 March 2023 At 31 March 2022 8 Stocks & Work in Progress Stocks before write downs 9 Debtors Prepayments and accrued income Other debtors	Land and Buildings £ - -	Plant & Machinery £ 2,500 1,599	Motor Vehicles £ - -	Total Total £ £ 2,500 2,500 1,599 1,599
	-	4,099	-	4,099 4,099
	- -	1,250 1,025	- -	1,250 1,250 1,025 1,025
	-	2,275	-	2,275 2,275
	-	1,824	-	1,824 1,824
	-	1,250	-	1,250 1,250
			2023 £ 17,490	2022 £ 17,507 17,507 2022 £ 485 3,947 4,432
			17,490
			2023 £ 280 3,947
			5,060

19

Leukaemia & Myeloma Research UK Ltd

Notes to the Accounts for the year ended 31 March 2023

10 Creditors: amounts falling due within one year Trade creditors Accruals 11 Income and Expenditure account summary At 1 April 2022 Surplus after tax for the year At 31 March 2023	2023 £ 3,643 1,920	2022 £ 3,916 2,290
	5,563	6,206
	2023 £ 316,847 35,474	2022 £ 286,288 30,559
	352,321	316,847

12 Particulars of how particular funds are represented by assets and liabilities

At 31 March 2023 Tangible Fixed Assets Current Assets Current Liabilities At 1 April 2022 Tangible Fixed Assets Current Assets Current Liabilities	Unrestricted funds £ 1,824 315,474 (5,563)	Designated funds £ - -	Restricted funds £ - 40,586 -	Total Total Funds Funds £ £ 1,824 1,824 356,060 356,060 (5,563) (5,563)
	311,735	-	40,586	352,321 352,321
	Unrestricted funds £ 1,250 290,286 (6,206)	Designated funds £ - - -	Restricted funds £ - 31,517 -	Total Total Funds Funds £ £ 1,250 1,250 321,803 321,803 (6,206) (6,206)
	285,330	-	31,517	316,847 316,847

20

Leukaemia & Myeloma Research UK Ltd

Notes to the Accounts for the year ended 31 March 2023

13 Change in total funds over the year as shown in Note 12 , analysed by individual funds

Unrestricted and designated funds:- Unrestricted Revenue Funds Total unrestricted and designated funds Restricted funds:- Model Cell Biobank Total restricted funds Total charity funds	Funds brought forward from 2022 £ 285,330	Movement in funds in 2023 See Note 14 £ 26,405	£ - Transfers between funds in 2023	Funds carried forward to 2024 £ £ 311,735 311,735 Funds carried forward to 2024
	285,330	26,405	-	311,735 311,735
	31,517	9,069	-	40,586 40,586
	31,517	9,069	-	40,586 40,586
	316,847	35,474	-	352,321 352,321

14 Analysis of movements in funds over the year as shown in Note 13

Unrestricted and designated funds:- Unrestricted Revenue Funds Restricted funds:- Model Cell Biobank	Income 2023 £ 207,953 37,303	Expenditure 2023 £ (181,548) (28,234)	Gains & Losses 2023 £ - -	Movement Movement in funds in funds 2023 2023 £ £ 26,405 26,405 9,069 9,069
	245,256	(209,782)	-	35,474 35,474

21

Leukaemia & Myeloma Research UK Ltd

Notes to the Accounts for the year ended 31 March 2023

15 The purposes for which the funds

Unrestricted and designated funds:- Unrestricted Revenue Funds

These funds are held for the meeting the objectives of the charity, and to provide reserves for future activities, research grants, and, subject to charity legislation, are free from all restrictions on their use.

Restricted funds:- Model Cell Biobank

The purpose of these funds is described under the accounting policy.

16 Ultimate controlling party

The charity is under the control of its legal members.

Every member of the charity is obliged to contribute such amount as may be required not exceeding £10 to the assets of the company in the event of its being wound up while he or she is a member, or within one year after he or she ceases to be a member.

22

Leukaemia & Myeloma Research UK Ltd

Detailed analysis of income and expenditure for the year ended 31 March 2023 as required by the SORP 2015

This analysis is classsified by conventional nominal descriptions and not by activity.

17 Donations, Grants and Legacies

Donations, Grants and Legacies
Donations and gifts from individuals Stripe direct donations Holyhead Road Unit Holyhead Church Facebook Just Giving Kiltwalk In Memory Fundraising Support Muchloved Virgin Money Giving Giving.com Paypal Giving Small donations individually less than £1000 Total donations and gifts from individuals Refunds from HMRC on gift aided donations	Current year Unrestricted Funds 2023 £ 8,415 - 14,707 6,536 2,523 47,846 2,880 17,856 - 7,859 - 2,646 2,895	Current year Restricted Funds 2023 £ - - - - - - - - - - - - - -	Current year Total Funds 2023 £ 8,415 - 14,707 6,536 2,523 47,846 2,880 17,856 - 7,859 - 2,646 2,895 114,163	Prior Year Total Funds 2022 £ 7,410 68 7,995 - 3,782 17,827 1,193 9,028 - 3,545 2,453 2,379 1,066
	114,163			56,746

All the donations and gifts in the prior year were unrestricted.

Donations and gifts from individuals (Include HMRC refunds on gift aided donations) - Prior Year analysis

	Prior Year	Prior Year	Prior Year
	Unrestricted	Restricted	Total Funds
	Funds	Funds
	2022	2022	2022
	£	£	£
Prior year	44,506	12,240	56,746

23

Leukaemia & Myeloma Research UK Ltd

Detailed analysis of income and expenditure for the year ended 31 March 2023 as required by the SORP 2015

Legacies receivable Legacies receivable Small legacies individually less than £1000 Mrs Mary Dallas Mrs Beryl Mary Round Mayo Wynne Baxter Solicitors Sylvia Allanson Malcolm Squibb Legacies receivable - Prior Year analysis Prior year Total legacies receivable	Current year Unrestricted Funds 2023 £ - - - - 1,500 5,000	Current year Restricted Funds 2023 £ - - - - - - - Prior Year Restricted Funds 2022 £ -	Current year Total Funds 2023 £ - - - - 1,500 5,000 6,500 Prior Year Total Funds 2022 £ 40,948	Prior Year Total Funds 2022 £ - 100 40,784 64 - -
	6,500			40,948
	Prior Year Unrestricted Funds 2022 £ 40,948

24

Leukaemia & Myeloma Research UK Ltd

Detailed analysis of income and expenditure for the year ended 31 March 2023 as required by the SORP 2015

Revenue grants from government and public bodies

Small grants individually less than £1000 Irwin Mitchell LLP / Ambergate Santa Barabara Heights Cjaritable Trust Thomas Sivewright Catto Charitable Trust The Tony Bramall Charitable Trust The Family Rich Charities Trust L&R Gilley Charitable Trust Gisela Graham Foundation The Constance Paterson Charitable Trust The Ian Askew Charitable Trust Charities Trust AVIVA Crowdfunder The Caron Keating Foundation The Hospital Saturday Fund May Nearnshaw Charitbale Trust Ladbrokes Coral Trust The Gledswood Charitable Trust Dorothy Homes Charitable Trust CAF/Box Power Foundation The Thomas Sivewright Catto Charitable Trust Sir Cliff Richard Albert Hunt Arnold Clark Total public sector revenue grants Revenue grants from government and public bodies	Current year Unrestricted Funds 2023 £ 2,500 - - - - - - - - - - - - - - - - 1,000 1,000	Current year Restricted Funds 2023 £ 200 2,000 1,000 1,000 1,000 5,000 - 2,000 - 1,000 - - - - 2,000 2,500 5,000 5,000 - - - - 27,700	Current year Total Funds 2023 £ 2,700 2,000 1,000 1,000 1,000 5,000 - 2,000 - 1,000 - - - - 2,000 2,500 5,000 5,000 - - - 1,000 1,000 32,200	Prior Year Total Funds 2022 £ 1,240 - - - - - 2,500 - 2,500 1,000 3,268 247 3,000 2,000 10,000 1,000 1,000 1,000
	4,500			28,755

Revenue grants from government and public bodies - Prior Year analysis

Prior Year	Prior Year Unrestricted Funds 2022 £ 28,755	Prior Year Restricted Funds 2022 £ -	Prior Year Total Funds 2022 £ 28,755

25

Leukaemia & Myeloma Research UK Ltd

Detailed analysis of income and expenditure for the year ended 31 March 2023 as required by the SORP 2015

Lunya Limited Fundraising Support Ltd Total private sector revenue grants Theatrical Society LPC Group Revenue grants and donations from non public bodies Orion Engineering	Current year Unrestricted Funds 2023 £ - - 10,000 427 3,000	Current year Restricted Funds 2023 £ - 7,685 - - - 7,685	Current year Total Funds 2023 £ - 7,685 10,000 427 3,000	Prior Year Total Funds 2022 £ 8,000 4,178 - - - 12,178
	13,427		21,112

Revenue grants and donations from non public bodies (Include Gift Aid donations from subsidiaries) - Prior Year analysis

Prior Year	Prior Year Unrestricted Funds 2022 £ 12,178	Prior Year Restricted Funds 2022 £ -	Prior Year Total Funds 2022 £ 12,178

26

Leukaemia & Myeloma Research UK Ltd

Detailed analysis of income and expenditure for the year ended 31 March 2023 as required by the SORP 2015

Total Donations, Grants and Legacies

Total Donations, Grants and Legacies
Current year Unrestricted Funds 2023 £ Total Donations, Grants and Legacies A1 138,590 All the donations and gifts in the prior year were unrestricted. Prior year Unrestricted Funds 2022 £ Total Donations, Grants and Legacies A1 126,387	Unrestricted Funds 2023 £	Restricted Funds 2023 £ 35,385 Restricted Funds 2022 £ 12,240	Current Year Total Funds 2023 £ 173,975 Prior Year Total Funds 2022 £ 138,627	Prior Year Total Funds 2022 £
	138,590			138,627
	126,387

27

Leukaemia & Myeloma Research UK Ltd

Detailed analysis of income and expenditure for the year ended 31 March 2023 as required by the SORP 2015

18 Income from charitable activities - Trading Activities

18 Income from charitable activities - Trading Activiti	es
Current year Primary purpose and ancillary trading Prior year Primary purpose and ancillary trading Total Primary purpose and ancillary trading 19 Current year Total income from charitable trading Total from charitable activities A2 Income from charitable activities - Prior Year analysis Prior year Total income from charitable trading Sale of goods and services in accordance with the charity's objects Total Primary purpose and ancillary trading Sale of goods and services in accordance with the charity's objects Total Income from charitable activities	Current year Unrestricted Funds 2023 £ 18,635	Current year Restricted Funds 2023 £ 1,918 1,918 Prior Year Restricted Funds 2022 £ - - Current year Restricted Funds 2023 £ 1,918 1,918 Prior Year Restricted Funds 2022 £ - -	Current year Total Funds 2023 £ 20,553 20,553 Prior Year Total Funds 2022 £ 17,846 17,846 Current year Total Funds 2023 £ 20,553 20,553 Prior Year Total Funds 2022 £ 17,846 17,846	Prior Year Total funds 2022 £ 17,846
	18,635			17,846
	Prior Year Unrestricted Funds 2022 £ 17,846			Prior Year Total Funds 2022 £ 17,846
	17,846
	Current year Unrestricted Funds 2023 £ 18,635
	18,635			17,846
	Prior Year Unrestricted Funds 2022 £ 17,846
	17,846

28

Leukaemia & Myeloma Research UK Ltd

Detailed analysis of income and expenditure for the year ended 31 March 2023 as required by the SORP 2015

20 Investment income

20 Investment income
Bank Interest Receivable Total investment income A4 21 Other income and gains Current year Total other income A5 Other income and gains - Prior year analysis Prior Year Total other income A5 Royalties from the exploitation of intellectual property rights Sundry other income Royalties from the exploitation of intellectual property rights Sundry other income	Current year Unrestricted Funds 2023 £ 665	Current year Restricted Funds 2023 £ - - Current year Restricted Funds 2023 £ - - - Prior Year Restricted Funds 2022 £ - - -	Current year Total Funds 2023 £ 665 665 Current year Total Funds 2023 £ 50,063 - 50,063 Prior Year Total Funds 2022 £ 50,000 109 50,109	Prior Year Total Funds 2022 £ 27
	665			27
	Current year Unrestricted Funds 2023 £ 50,063 -			Prior Year Total Funds 2022 £ 50,000 109
	50,063			50,109
	Prior Year Unrestricted Funds 2022 £ 50,000 109
	50,109

29

Leukaemia & Myeloma Research UK Ltd

Detailed analysis of income and expenditure for the year ended 31 March 2023 as required by the SORP 2015

22 Expenditure on charitable activities - Direct spending

Current Year Total direct spending B2a Prior Year Total direct spending B2a Costs of activities and events Travel and Subsistence - Charitable Activities Costs of activities and events Consultancy and professional support Consultancy and professional support Travel and Subsistence - Charitable Activities Travel and Subsistence - Trustees Travel Expenses	Current year Unrestricted Funds 2023 £ 218 11,559 33,333 1,292	Current year Restricted Funds 2023 £ - 25,102 - - 25,102 Prior Year Restricted Funds 2022 £ - 10,585 - 10,585	Current year Total Funds 2023 £ 218 36,661 33,333 1,292 71,504 Prior Year Total Funds 2022 £ 1,931 20,683 24,636 47,250	Prior Year Total Funds 2022 £ 1,931 20,683 24,636 -
	46,402			47,250
	Prior Year Unrestricted Funds 2022 £ 1,931 10,098 24,636
	36,665

30

Leukaemia & Myeloma Research UK Ltd

Detailed analysis of income and expenditure for the year ended 31 March 2023 as required by the SORP 2015

23 Expenditure on charitable activities - Charitable trading

Current Year Total charitable trading costs B2b Cost of goods for primary purpose trading - Including movement in stock for goods made by beneficiaries	Current year Unrestricted Funds 2023 £ 7,874	Current year Restricted Funds 2023 £ - -	Current year Prior Year Total Funds Total Funds 2023 2022 £ £ 7,874 11,198
	7,874		7,874 11,198

24 Expenditure on charitable activities- Grant funding of activities

Current Year Total grantmaking costs B2c Grants made to organisations	Current year Unrestricted Funds 2023 £ 25,000	Current year Restricted Funds 2023 £ - -	Current year Prior Year Total Funds Total Funds 2023 2022 £ £ 25,000 24,251
	25,000		25,000 24,251

31

Leukaemia & Myeloma Research UK Ltd

Detailed analysis of income and expenditure for the year ended 31 March 2023 as required by the SORP 2015

25 Support costs for charitable activities

25 Support costs for charitable activities
Current year Current year Current Year Unrestricted Funds Restricted Funds 2023 2023 £ £ Premises Expenses Rates and water charges 219 - Rent and rates 24,212 - 17 - - - 686 - 596 - Administrative overheads 2,184 - 698 - 1,480 - Shipping, freight and delivery - - Membership subscriptions 7,895 - 2,199 - 1,099 - 2,119 1,979 10,603 1,143 - - Professional fees paid to advisors other than the auditor or examiner 710 - 26,735 10 660 - Financial costs 35 - 1,025 - Support costs before reallocation 83,172 3,132 Total support costs - Current Year 83,172 3,132 The basis of allocation of costs between activities is described under accounting policies Bank charges Accountancy fees other than examination or audit fees Management fees Property insurance Light heat and power Telephone, fax and internet Postage Cleaning and waste management Stationery and printing Hire of equipment Equipment expenses Equipment repairs,expenses and maintenance Software licences and expenses Premises repairs, renewals and maintenance Advertising and marketing Depreciation & Amortisation in total for Other legal and professional	Current year Total Funds 2023 £ 219 24,212 17 - 686 596 2,184 698 1,480 - 7,895 2,199 1,099 4,098 11,746 - 710 26,745 660 35 1,025	Prior Year Total Funds 2022 £ 249 23,206 414 216 4,098 428 2,365 582 416 840 7,381 3,167 1,058 2,332 13,502 325 1,080 21,528 - 24 625
	86,304 86,304	83,836
		83,836

32

Leukaemia & Myeloma Research UK Ltd

Detailed analysis of income and expenditure for the year ended 31 March 2023 as required by the SORP 2015

Prior Year Premises Expenses Rates and water charges Rent and rates Light heat and power Cleaning and waste management Premises repairs, renewals and maintenance Property insurance Administrative overheads Telephone, fax and internet Postage Stationery and printing Shipping, freight and delivery Membership subscriptions Equipment expenses Hire of equipment Software licences and expenses Advertising and marketing Equipment repairs,expenses and maintenance Accountancy fees other than examination or audit fees Management fees Financial costs Bank charges Depreciation & Amortisation in total for the period Support costs before reallocation Professional fees paid to advisors other than the auditor or examiner Total support costs - Prior Year	Current year Unrestricted Funds 2023 £ 249 23,206 414 216 4,098 428 2,042 483 416 840 7,381 3,167 1,058 1,426 12,433 325 1,080 21,528 24 625	Current year Restricted Funds 2023 £ - - - - - - 323 99 - - - - - 906 1,069 - - - - - 2,397 2,397	Prior Year Total Funds 2022 £ 249 23,206 414 216 4,098 428 2,365 582 416 840 7,381 3,167 1,058 2,332 13,502 325 1,080 21,528 24 625
	81,439		83,836 83,836
	81,439

The basis of allocation of costs between activities is described under accounting policies

33

Leukaemia & Myeloma Research UK Ltd

Detailed analysis of income and expenditure for the year ended 31 March 2023 as required by the SORP 2015

26 Other Expenditure - Governance costs

Current Year Independent Examiner's fees Total Governance costs	Current year Unrestricted Funds 2023 £ -	Current year Restricted Funds 2023 £ - -	Current year Total Funds 2023 £ - -	Prior Year Total Funds 2022 £ 420
	-			420

All the expenditure in the prior year was unrestricted.

27 Total Charitable expenditure

Total Charitable expenditure
Current Year Total direct spending B2a Total charitable trading costs B2b Total grantmaking costs B2c Total support costs B2d Total Governance costs B2e Total charitable expenditure B2 Prior Year Total direct spending B2a Total charitable trading costs B2b Total grantmaking costs B2c Total support costs B2d Total Governance costs B2e Total charitable expenditure B2	Current year Unrestricted Funds 2023 £ 46,402 7,874 25,000 83,172 -	Current year Restricted Funds 2023 £ 25,102 - - 3,132 - 28,234 Prior Year Restricted Funds 2022 £ 10,585 - - 2,397 -	Current year Total Funds 2023 £ 71,504 7,874 25,000 86,304 - 190,682 Prior Year Total Funds 2022 £ 47,250 11,198 24,251 83,836 420	Prior Year Total Funds 2022 £ 47,250 11,198 24,251 83,836 420
	162,448			166,955
	Prior Year Unrestricted Funds 2022 £ 36,665 11,198 24,251 81,439 420
	153,973	12,982	166,955

34

Leukaemia & Myeloma Research UK Ltd

Detailed analysis of income and expenditure for the year ended 31 March 2023 as required by the SORP 2015

28 Expenditure on raising funds and costs of investment management

Current Year Agent's costs for fundraising Fundraising publicity & marketing Cost of fundraising activities Fundraising trading costs Total fundraising costs B1	Current year Unrestricted Funds 2023 £ 6,450 - 11,996 654	Current year Restricted Funds 2023 £ - - - - -	Current year Prior Year Total Funds Total Funds 2023 2022 £ £ 6,450 4,945 - 480 11,996 2,764 654 906
	19,100		19,100 9,095

All the expenditure in the prior year was unrestricted.

35